Randomized Phase II 2x2 Factorial Trial Of The Addition of Carboplatin
And/Or Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense
AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
||Paula Klein, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
The purpose of the study is to see if adding other drugs to standard neoadjuvant
chemotherapy can help shrink triple-negative breast cancer faster, and
lower the risk of the cancer coming back in other part of the body.
In addition to studying their effectiveness, the study is designed to
find out how frequently patients have side effects from these treatments.
We are also studying a number of biologic characteristics in the cancer
cells and blood of patients like you to see whether those characteristics
predict which patients are more likely to achieve a pCR and which patients
may benefit from the addition of carboplatin and/or bevacizumab to the
standard treatment regimen.
Age 18 or older
Stage II-III invasive breast cancer with intent to perform surgical resection
after neoadjuvant therapy
Invasive tumor must be hormone receptor-poor and HER2-negative
Patient must agree to undergo pretreatment research biopsies.
Please call for more information.